Compare FTAI Aviation Ltd (FTAI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Novo Nordisk A/S — how do they compare? FTAI Aviation Ltd trades at $169.68 (market cap $17.57B), while Novo Nordisk A/S trades at $38.52 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 9.4× FTAI Aviation Ltd's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 22 Days and Novo Nordisk A/S for 116 Days on average.
| FTAI | NVO | |
|---|---|---|
Market Cap | $17.57B | $165.31B |
Volume | 1,905,014 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $310.04 | $63.98 |
52-Week Low | $152.80 | $35.29 |
Typical Hold Time | 22 Days | 116 Days |
Enterprise Value | $20.69B | $179.56B |
Dividend Yield | 1.17% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation Ltd. (FTAI) trades at $169.13, down 3.26% over 24 hours, with a bearish technical signal from moving averages. Recent financials show strong revenue growth to $2.51B in 2025 and a net income margin of 15.94%, but earnings have missed expectations for three consecutive quarters. The company announced a $500 million share repurchase program and a strategic aircraft acquisition, signaling management confidence. Valuation ratios are elevated, with a P/E of 37.35 and P/B of 43.49, reflecting high growth expectations.
The outlook for FTAI is mixed; analyst consensus is unanimously bullish with a $321.25 price target, but near-term risks include earnings misses and negative operating cash flow. Long-term growth drivers include expansion in aerospace products and power segments, though execution risks and market volatility could pressure the stock. Investors should weigh strong institutional support against fundamental headwinds.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
